Senate File 282 - Introduced


                                 SENATE FILE 

                                 SENATE FILE 
                                 SENATE FILE                                  SENATE FILE                                  BY  ZAUN

 A BILL FOR

  1 An Act relating to the medical use of cannabidiol including
  2    the rescheduling of a cannabidiol investigational product
  3    approved as a prescription drug medication under federal law
  4    and including effective date provisions.
  5 BE IT ENACTED BY THE GENERAL ASSEMBLY OF THE STATE OF IOWA:
    TLSB 2301XS (2) 87
    rh/rj

PAG LIN



  1  1    Section 1.  Section 124.201, Code 2017, is amended by adding
  1  2 the following new subsection:
  1  3    
 A BILL FOR

  1 An Act relating to the medical use of cannabidiol including
  2    the rescheduling of a cannabidiol investigational product
  3    approved as a prescription drug medication under federal law
  4    and including effective date provisions.
  5 BE IT ENACTED BY THE GENERAL ASSEMBLY OF THE STATE OF IOWA:
    TLSB 2301XS (2) 87
    rh/rj

PAG LIN



  1  1    Section 1.  Section 124.201, Code 2017, is amended by adding
  1  2 the following new subsection:
  1  3     A BILL FOR

  1 An Act relating to the medical use of cannabidiol including
  2    the rescheduling of a cannabidiol investigational product
  3    approved as a prescription drug medication under federal law
  4    and including effective date provisions.
  5 BE IT ENACTED BY THE GENERAL ASSEMBLY OF THE STATE OF IOWA:
    TLSB 2301XS (2) 87
    rh/rj

PAG LIN



  1  1    Section 1.  Section 124.201, Code 2017, is amended by adding
  1  2 the following new subsection:
  1  3    
  1 An Act relating to the medical use of cannabidiol including
  2    the rescheduling of a cannabidiol investigational product
  3    approved as a prescription drug medication under federal law
  4    and including effective date provisions.
  5 BE IT ENACTED BY THE GENERAL ASSEMBLY OF THE STATE OF IOWA:
    TLSB 2301XS (2) 87
    rh/rj

PAG LIN



  1  1    Section 1.  Section 124.201, Code 2017, is amended by adding
  1  2 the following new subsection:
  1  3      1 An Act relating to the medical use of cannabidiol including
  2    the rescheduling of a cannabidiol investigational product
  3    approved as a prescription drug medication under federal law
  4    and including effective date provisions.
  5 BE IT ENACTED BY THE GENERAL ASSEMBLY OF THE STATE OF IOWA:
    TLSB 2301XS (2) 87
    rh/rj

PAG LIN



  1  1    Section 1.  Section 124.201, Code 2017, is amended by adding
  1  2 the following new subsection:
  1  3      2    the rescheduling of a cannabidiol investigational product
  3    approved as a prescription drug medication under federal law
  4    and including effective date provisions.
  5 BE IT ENACTED BY THE GENERAL ASSEMBLY OF THE STATE OF IOWA:
    TLSB 2301XS (2) 87
    rh/rj

PAG LIN



  1  1    Section 1.  Section 124.201, Code 2017, is amended by adding
  1  2 the following new subsection:
  1  3      3    approved as a prescription drug medication under federal law
  4    and including effective date provisions.
  5 BE IT ENACTED BY THE GENERAL ASSEMBLY OF THE STATE OF IOWA:
    TLSB 2301XS (2) 87
    rh/rj

PAG LIN



  1  1    Section 1.  Section 124.201, Code 2017, is amended by adding
  1  2 the following new subsection:
  1  3      4    and including effective date provisions.
  5 BE IT ENACTED BY THE GENERAL ASSEMBLY OF THE STATE OF IOWA:
    TLSB 2301XS (2) 87
    rh/rj

PAG LIN



  1  1    Section 1.  Section 124.201, Code 2017, is amended by adding
  1  2 the following new subsection:
  1  3      5 BE IT ENACTED BY THE GENERAL ASSEMBLY OF THE STATE OF IOWA:
    TLSB 2301XS (2) 87
    rh/rj

PAG LIN



  1  1    Section 1.  Section 124.201, Code 2017, is amended by adding
  1  2 the following new subsection:
  1  3        TLSB 2301XS (2) 87
    rh/rj

PAG LIN



  1  1    Section 1.  Section 124.201, Code 2017, is amended by adding
  1  2 the following new subsection:
  1  3        rh/rj

PAG LIN



  1  1    Section 1.  Section 124.201, Code 2017, is amended by adding
  1  2 the following new subsection:
  1  3    

  1  1    Section 1.  Section 124.201, Code 2017, is amended by adding
  1  2 the following new subsection:
  1  3    
  1  1    Section 1.  Section 124.201, Code 2017, is amended by adding
  1  2 the following new subsection:
  1  3      1  1    Section 1.  Section 124.201, Code 2017, is amended by adding
  1  2 the following new subsection:
  1  3      1  2 the following new subsection:
  1  3      1  3      1  4 product approved as a prescription drug medication by the
  1  5 United States food and drug administration is designated
  1  6 as a schedule II controlled substance by the federal drug
  1  7 enforcement agency, the board shall, upon notice of the
  1  8 designation, similarly designate the prescription drug
  1  9 medication as a schedule II controlled substance under this
  1 10 chapter.  Such designation by the board shall be immediately
  1 11 effective upon the date of publication in the federal register
  1 12 of the final order designating the prescription drug medication
  1 13 as a schedule II controlled substance.
  1 14    b.  The board shall adopt rules pursuant to chapter 17A to
  1 15 administer this subsection.  The board may adopt rules on an
  1 16 emergency basis as provided in section 17A.4, subsection 3, and
  1 17 section 17A.5, subsection 2, to administer this subsection,
  1 18 and the rules shall be effective immediately upon filing
  1 19 unless a later date is specified in the rules.  Any emergency
  1 20 rules adopted in accordance with this subsection shall also be
  1 21 published as a notice of intended action as provided in section
  1 22 17A.4, subsection 1.
  1 23    Sec. 2.  REPEAL.  Section 124D.8, Code 2017, is repealed.
  1 24    Sec. 3.  EFFECTIVE DATE.  The section of this Act repealing
  1 25 section 124D.8, Code 2017, takes effect June 30, 2017.
  1 26                           EXPLANATION
  1 27 The inclusion of this explanation does not constitute agreement with
  1 28 the explanation's substance by the members of the general assembly.
  1 29    This bill relates to the medical use of cannabidiol,
  1 30 including the rescheduling of a cannabidiol investigational
  1 31 product approved as a prescription drug medication under
  1 32 federal law.
  1 33    The bill provides if a cannabidiol investigational product
  1 34 approved as a prescription drug medication by the United States
  1 35 food and drug administration is designated as a schedule II
  2  1 controlled substance by the federal drug enforcement agency,
  2  2 the board of pharmacy shall, upon notice of the designation,
  2  3 similarly designate the prescription drug medication as
  2  4 a schedule II controlled substance.  Such designation by
  2  5 the board shall be immediately effective upon the date
  2  6 of publication in the federal register of the final order
  2  7 designating the prescription drug medication as a schedule II
  2  8 controlled substance.
  2  9    The bill provides that the board shall adopt rules pursuant
  2 10 to Code chapter 17A to administer the bill and may adopt
  2 11 emergency rules which shall be effective immediately upon
  2 12 filing unless a later date is specified in the rules.  Any
  2 13 emergency rules adopted shall also be published as a notice of
  2 14 intended action as provided in Code section 17A.4, subsection
  2 15 1.
  2 16    The bill strikes the repeal of Code chapter 124D (medical
  2 17 cannabidiol Act) before the repeal becomes effective July 1,
  2 18 2017.
       LSB 2301XS (2) 87
       rh/rj
  1  5 United States food and drug administration is designated
  1  6 as a schedule II controlled substance by the federal drug
  1  7 enforcement agency, the board shall, upon notice of the
  1  8 designation, similarly designate the prescription drug
  1  9 medication as a schedule II controlled substance under this
  1 10 chapter.  Such designation by the board shall be immediately
  1 11 effective upon the date of publication in the federal register
  1 12 of the final order designating the prescription drug medication
  1 13 as a schedule II controlled substance.
  1 14    b.  The board shall adopt rules pursuant to chapter 17A to
  1 15 administer this subsection.  The board may adopt rules on an
  1 16 emergency basis as provided in section 17A.4, subsection 3, and
  1 17 section 17A.5, subsection 2, to administer this subsection,
  1 18 and the rules shall be effective immediately upon filing
  1 19 unless a later date is specified in the rules.  Any emergency
  1 20 rules adopted in accordance with this subsection shall also be
  1 21 published as a notice of intended action as provided in section
  1 22 17A.4, subsection 1.
  1 23    Sec. 2.  REPEAL.  Section 124D.8, Code 2017, is repealed.
  1 24    Sec. 3.  EFFECTIVE DATE.  The section of this Act repealing
  1 25 section 124D.8, Code 2017, takes effect June 30, 2017.
  1 26                           EXPLANATION
  1 27 The inclusion of this explanation does not constitute agreement with
  1 28 the explanation's substance by the members of the general assembly.
  1 29    This bill relates to the medical use of cannabidiol,
  1 30 including the rescheduling of a cannabidiol investigational
  1 31 product approved as a prescription drug medication under
  1 32 federal law.
  1 33    The bill provides if a cannabidiol investigational product
  1 34 approved as a prescription drug medication by the United States
  1 35 food and drug administration is designated as a schedule II
  2  1 controlled substance by the federal drug enforcement agency,
  2  2 the board of pharmacy shall, upon notice of the designation,
  2  3 similarly designate the prescription drug medication as
  2  4 a schedule II controlled substance.  Such designation by
  2  5 the board shall be immediately effective upon the date
  2  6 of publication in the federal register of the final order
  2  7 designating the prescription drug medication as a schedule II
  2  8 controlled substance.
  2  9    The bill provides that the board shall adopt rules pursuant
  2 10 to Code chapter 17A to administer the bill and may adopt
  2 11 emergency rules which shall be effective immediately upon
  2 12 filing unless a later date is specified in the rules.  Any
  2 13 emergency rules adopted shall also be published as a notice of
  2 14 intended action as provided in Code section 17A.4, subsection
  2 15 1.
  2 16    The bill strikes the repeal of Code chapter 124D (medical
  2 17 cannabidiol Act) before the repeal becomes effective July 1,
  2 18 2017.
       LSB 2301XS (2) 87
       rh/rj
  1  6 as a schedule II controlled substance by the federal drug
  1  7 enforcement agency, the board shall, upon notice of the
  1  8 designation, similarly designate the prescription drug
  1  9 medication as a schedule II controlled substance under this
  1 10 chapter.  Such designation by the board shall be immediately
  1 11 effective upon the date of publication in the federal register
  1 12 of the final order designating the prescription drug medication
  1 13 as a schedule II controlled substance.
  1 14    b.  The board shall adopt rules pursuant to chapter 17A to
  1 15 administer this subsection.  The board may adopt rules on an
  1 16 emergency basis as provided in section 17A.4, subsection 3, and
  1 17 section 17A.5, subsection 2, to administer this subsection,
  1 18 and the rules shall be effective immediately upon filing
  1 19 unless a later date is specified in the rules.  Any emergency
  1 20 rules adopted in accordance with this subsection shall also be
  1 21 published as a notice of intended action as provided in section
  1 22 17A.4, subsection 1.
  1 23    Sec. 2.  REPEAL.  Section 124D.8, Code 2017, is repealed.
  1 24    Sec. 3.  EFFECTIVE DATE.  The section of this Act repealing
  1 25 section 124D.8, Code 2017, takes effect June 30, 2017.
  1 26                           EXPLANATION
  1 27 The inclusion of this explanation does not constitute agreement with
  1 28 the explanation's substance by the members of the general assembly.
  1 29    This bill relates to the medical use of cannabidiol,
  1 30 including the rescheduling of a cannabidiol investigational
  1 31 product approved as a prescription drug medication under
  1 32 federal law.
  1 33    The bill provides if a cannabidiol investigational product
  1 34 approved as a prescription drug medication by the United States
  1 35 food and drug administration is designated as a schedule II
  2  1 controlled substance by the federal drug enforcement agency,
  2  2 the board of pharmacy shall, upon notice of the designation,
  2  3 similarly designate the prescription drug medication as
  2  4 a schedule II controlled substance.  Such designation by
  2  5 the board shall be immediately effective upon the date
  2  6 of publication in the federal register of the final order
  2  7 designating the prescription drug medication as a schedule II
  2  8 controlled substance.
  2  9    The bill provides that the board shall adopt rules pursuant
  2 10 to Code chapter 17A to administer the bill and may adopt
  2 11 emergency rules which shall be effective immediately upon
  2 12 filing unless a later date is specified in the rules.  Any
  2 13 emergency rules adopted shall also be published as a notice of
  2 14 intended action as provided in Code section 17A.4, subsection
  2 15 1.
  2 16    The bill strikes the repeal of Code chapter 124D (medical
  2 17 cannabidiol Act) before the repeal becomes effective July 1,
  2 18 2017.
       LSB 2301XS (2) 87
       rh/rj
  1  7 enforcement agency, the board shall, upon notice of the
  1  8 designation, similarly designate the prescription drug
  1  9 medication as a schedule II controlled substance under this
  1 10 chapter.  Such designation by the board shall be immediately
  1 11 effective upon the date of publication in the federal register
  1 12 of the final order designating the prescription drug medication
  1 13 as a schedule II controlled substance.
  1 14    b.  The board shall adopt rules pursuant to chapter 17A to
  1 15 administer this subsection.  The board may adopt rules on an
  1 16 emergency basis as provided in section 17A.4, subsection 3, and
  1 17 section 17A.5, subsection 2, to administer this subsection,
  1 18 and the rules shall be effective immediately upon filing
  1 19 unless a later date is specified in the rules.  Any emergency
  1 20 rules adopted in accordance with this subsection shall also be
  1 21 published as a notice of intended action as provided in section
  1 22 17A.4, subsection 1.
  1 23    Sec. 2.  REPEAL.  Section 124D.8, Code 2017, is repealed.
  1 24    Sec. 3.  EFFECTIVE DATE.  The section of this Act repealing
  1 25 section 124D.8, Code 2017, takes effect June 30, 2017.
  1 26                           EXPLANATION
  1 27 The inclusion of this explanation does not constitute agreement with
  1 28 the explanation's substance by the members of the general assembly.
  1 29    This bill relates to the medical use of cannabidiol,
  1 30 including the rescheduling of a cannabidiol investigational
  1 31 product approved as a prescription drug medication under
  1 32 federal law.
  1 33    The bill provides if a cannabidiol investigational product
  1 34 approved as a prescription drug medication by the United States
  1 35 food and drug administration is designated as a schedule II
  2  1 controlled substance by the federal drug enforcement agency,
  2  2 the board of pharmacy shall, upon notice of the designation,
  2  3 similarly designate the prescription drug medication as
  2  4 a schedule II controlled substance.  Such designation by
  2  5 the board shall be immediately effective upon the date
  2  6 of publication in the federal register of the final order
  2  7 designating the prescription drug medication as a schedule II
  2  8 controlled substance.
  2  9    The bill provides that the board shall adopt rules pursuant
  2 10 to Code chapter 17A to administer the bill and may adopt
  2 11 emergency rules which shall be effective immediately upon
  2 12 filing unless a later date is specified in the rules.  Any
  2 13 emergency rules adopted shall also be published as a notice of
  2 14 intended action as provided in Code section 17A.4, subsection
  2 15 1.
  2 16    The bill strikes the repeal of Code chapter 124D (medical
  2 17 cannabidiol Act) before the repeal becomes effective July 1,
  2 18 2017.
       LSB 2301XS (2) 87
       rh/rj
  1  8 designation, similarly designate the prescription drug
  1  9 medication as a schedule II controlled substance under this
  1 10 chapter.  Such designation by the board shall be immediately
  1 11 effective upon the date of publication in the federal register
  1 12 of the final order designating the prescription drug medication
  1 13 as a schedule II controlled substance.
  1 14    b.  The board shall adopt rules pursuant to chapter 17A to
  1 15 administer this subsection.  The board may adopt rules on an
  1 16 emergency basis as provided in section 17A.4, subsection 3, and
  1 17 section 17A.5, subsection 2, to administer this subsection,
  1 18 and the rules shall be effective immediately upon filing
  1 19 unless a later date is specified in the rules.  Any emergency
  1 20 rules adopted in accordance with this subsection shall also be
  1 21 published as a notice of intended action as provided in section
  1 22 17A.4, subsection 1.
  1 23    Sec. 2.  REPEAL.  Section 124D.8, Code 2017, is repealed.
  1 24    Sec. 3.  EFFECTIVE DATE.  The section of this Act repealing
  1 25 section 124D.8, Code 2017, takes effect June 30, 2017.
  1 26                           EXPLANATION
  1 27 The inclusion of this explanation does not constitute agreement with
  1 28 the explanation's substance by the members of the general assembly.
  1 29    This bill relates to the medical use of cannabidiol,
  1 30 including the rescheduling of a cannabidiol investigational
  1 31 product approved as a prescription drug medication under
  1 32 federal law.
  1 33    The bill provides if a cannabidiol investigational product
  1 34 approved as a prescription drug medication by the United States
  1 35 food and drug administration is designated as a schedule II
  2  1 controlled substance by the federal drug enforcement agency,
  2  2 the board of pharmacy shall, upon notice of the designation,
  2  3 similarly designate the prescription drug medication as
  2  4 a schedule II controlled substance.  Such designation by
  2  5 the board shall be immediately effective upon the date
  2  6 of publication in the federal register of the final order
  2  7 designating the prescription drug medication as a schedule II
  2  8 controlled substance.
  2  9    The bill provides that the board shall adopt rules pursuant
  2 10 to Code chapter 17A to administer the bill and may adopt
  2 11 emergency rules which shall be effective immediately upon
  2 12 filing unless a later date is specified in the rules.  Any
  2 13 emergency rules adopted shall also be published as a notice of
  2 14 intended action as provided in Code section 17A.4, subsection
  2 15 1.
  2 16    The bill strikes the repeal of Code chapter 124D (medical
  2 17 cannabidiol Act) before the repeal becomes effective July 1,
  2 18 2017.
       LSB 2301XS (2) 87
       rh/rj
  1  9 medication as a schedule II controlled substance under this
  1 10 chapter.  Such designation by the board shall be immediately
  1 11 effective upon the date of publication in the federal register
  1 12 of the final order designating the prescription drug medication
  1 13 as a schedule II controlled substance.
  1 14    b.  The board shall adopt rules pursuant to chapter 17A to
  1 15 administer this subsection.  The board may adopt rules on an
  1 16 emergency basis as provided in section 17A.4, subsection 3, and
  1 17 section 17A.5, subsection 2, to administer this subsection,
  1 18 and the rules shall be effective immediately upon filing
  1 19 unless a later date is specified in the rules.  Any emergency
  1 20 rules adopted in accordance with this subsection shall also be
  1 21 published as a notice of intended action as provided in section
  1 22 17A.4, subsection 1.
  1 23    Sec. 2.  REPEAL.  Section 124D.8, Code 2017, is repealed.
  1 24    Sec. 3.  EFFECTIVE DATE.  The section of this Act repealing
  1 25 section 124D.8, Code 2017, takes effect June 30, 2017.
  1 26                           EXPLANATION
  1 27 The inclusion of this explanation does not constitute agreement with
  1 28 the explanation's substance by the members of the general assembly.
  1 29    This bill relates to the medical use of cannabidiol,
  1 30 including the rescheduling of a cannabidiol investigational
  1 31 product approved as a prescription drug medication under
  1 32 federal law.
  1 33    The bill provides if a cannabidiol investigational product
  1 34 approved as a prescription drug medication by the United States
  1 35 food and drug administration is designated as a schedule II
  2  1 controlled substance by the federal drug enforcement agency,
  2  2 the board of pharmacy shall, upon notice of the designation,
  2  3 similarly designate the prescription drug medication as
  2  4 a schedule II controlled substance.  Such designation by
  2  5 the board shall be immediately effective upon the date
  2  6 of publication in the federal register of the final order
  2  7 designating the prescription drug medication as a schedule II
  2  8 controlled substance.
  2  9    The bill provides that the board shall adopt rules pursuant
  2 10 to Code chapter 17A to administer the bill and may adopt
  2 11 emergency rules which shall be effective immediately upon
  2 12 filing unless a later date is specified in the rules.  Any
  2 13 emergency rules adopted shall also be published as a notice of
  2 14 intended action as provided in Code section 17A.4, subsection
  2 15 1.
  2 16    The bill strikes the repeal of Code chapter 124D (medical
  2 17 cannabidiol Act) before the repeal becomes effective July 1,
  2 18 2017.
       LSB 2301XS (2) 87
       rh/rj
  1 10 chapter.  Such designation by the board shall be immediately
  1 11 effective upon the date of publication in the federal register
  1 12 of the final order designating the prescription drug medication
  1 13 as a schedule II controlled substance.
  1 14    b.  The board shall adopt rules pursuant to chapter 17A to
  1 15 administer this subsection.  The board may adopt rules on an
  1 16 emergency basis as provided in section 17A.4, subsection 3, and
  1 17 section 17A.5, subsection 2, to administer this subsection,
  1 18 and the rules shall be effective immediately upon filing
  1 19 unless a later date is specified in the rules.  Any emergency
  1 20 rules adopted in accordance with this subsection shall also be
  1 21 published as a notice of intended action as provided in section
  1 22 17A.4, subsection 1.
  1 23    Sec. 2.  REPEAL.  Section 124D.8, Code 2017, is repealed.
  1 24    Sec. 3.  EFFECTIVE DATE.  The section of this Act repealing
  1 25 section 124D.8, Code 2017, takes effect June 30, 2017.
  1 26                           EXPLANATION
  1 27 The inclusion of this explanation does not constitute agreement with
  1 28 the explanation's substance by the members of the general assembly.
  1 29    This bill relates to the medical use of cannabidiol,
  1 30 including the rescheduling of a cannabidiol investigational
  1 31 product approved as a prescription drug medication under
  1 32 federal law.
  1 33    The bill provides if a cannabidiol investigational product
  1 34 approved as a prescription drug medication by the United States
  1 35 food and drug administration is designated as a schedule II
  2  1 controlled substance by the federal drug enforcement agency,
  2  2 the board of pharmacy shall, upon notice of the designation,
  2  3 similarly designate the prescription drug medication as
  2  4 a schedule II controlled substance.  Such designation by
  2  5 the board shall be immediately effective upon the date
  2  6 of publication in the federal register of the final order
  2  7 designating the prescription drug medication as a schedule II
  2  8 controlled substance.
  2  9    The bill provides that the board shall adopt rules pursuant
  2 10 to Code chapter 17A to administer the bill and may adopt
  2 11 emergency rules which shall be effective immediately upon
  2 12 filing unless a later date is specified in the rules.  Any
  2 13 emergency rules adopted shall also be published as a notice of
  2 14 intended action as provided in Code section 17A.4, subsection
  2 15 1.
  2 16    The bill strikes the repeal of Code chapter 124D (medical
  2 17 cannabidiol Act) before the repeal becomes effective July 1,
  2 18 2017.
       LSB 2301XS (2) 87
       rh/rj
  1 11 effective upon the date of publication in the federal register
  1 12 of the final order designating the prescription drug medication
  1 13 as a schedule II controlled substance.
  1 14    b.  The board shall adopt rules pursuant to chapter 17A to
  1 15 administer this subsection.  The board may adopt rules on an
  1 16 emergency basis as provided in section 17A.4, subsection 3, and
  1 17 section 17A.5, subsection 2, to administer this subsection,
  1 18 and the rules shall be effective immediately upon filing
  1 19 unless a later date is specified in the rules.  Any emergency
  1 20 rules adopted in accordance with this subsection shall also be
  1 21 published as a notice of intended action as provided in section
  1 22 17A.4, subsection 1.
  1 23    Sec. 2.  REPEAL.  Section 124D.8, Code 2017, is repealed.
  1 24    Sec. 3.  EFFECTIVE DATE.  The section of this Act repealing
  1 25 section 124D.8, Code 2017, takes effect June 30, 2017.
  1 26                           EXPLANATION
  1 27 The inclusion of this explanation does not constitute agreement with
  1 28 the explanation's substance by the members of the general assembly.
  1 29    This bill relates to the medical use of cannabidiol,
  1 30 including the rescheduling of a cannabidiol investigational
  1 31 product approved as a prescription drug medication under
  1 32 federal law.
  1 33    The bill provides if a cannabidiol investigational product
  1 34 approved as a prescription drug medication by the United States
  1 35 food and drug administration is designated as a schedule II
  2  1 controlled substance by the federal drug enforcement agency,
  2  2 the board of pharmacy shall, upon notice of the designation,
  2  3 similarly designate the prescription drug medication as
  2  4 a schedule II controlled substance.  Such designation by
  2  5 the board shall be immediately effective upon the date
  2  6 of publication in the federal register of the final order
  2  7 designating the prescription drug medication as a schedule II
  2  8 controlled substance.
  2  9    The bill provides that the board shall adopt rules pursuant
  2 10 to Code chapter 17A to administer the bill and may adopt
  2 11 emergency rules which shall be effective immediately upon
  2 12 filing unless a later date is specified in the rules.  Any
  2 13 emergency rules adopted shall also be published as a notice of
  2 14 intended action as provided in Code section 17A.4, subsection
  2 15 1.
  2 16    The bill strikes the repeal of Code chapter 124D (medical
  2 17 cannabidiol Act) before the repeal becomes effective July 1,
  2 18 2017.
       LSB 2301XS (2) 87
       rh/rj
  1 12 of the final order designating the prescription drug medication
  1 13 as a schedule II controlled substance.
  1 14    b.  The board shall adopt rules pursuant to chapter 17A to
  1 15 administer this subsection.  The board may adopt rules on an
  1 16 emergency basis as provided in section 17A.4, subsection 3, and
  1 17 section 17A.5, subsection 2, to administer this subsection,
  1 18 and the rules shall be effective immediately upon filing
  1 19 unless a later date is specified in the rules.  Any emergency
  1 20 rules adopted in accordance with this subsection shall also be
  1 21 published as a notice of intended action as provided in section
  1 22 17A.4, subsection 1.
  1 23    Sec. 2.  REPEAL.  Section 124D.8, Code 2017, is repealed.
  1 24    Sec. 3.  EFFECTIVE DATE.  The section of this Act repealing
  1 25 section 124D.8, Code 2017, takes effect June 30, 2017.
  1 26                           EXPLANATION
  1 27 The inclusion of this explanation does not constitute agreement with
  1 28 the explanation's substance by the members of the general assembly.
  1 29    This bill relates to the medical use of cannabidiol,
  1 30 including the rescheduling of a cannabidiol investigational
  1 31 product approved as a prescription drug medication under
  1 32 federal law.
  1 33    The bill provides if a cannabidiol investigational product
  1 34 approved as a prescription drug medication by the United States
  1 35 food and drug administration is designated as a schedule II
  2  1 controlled substance by the federal drug enforcement agency,
  2  2 the board of pharmacy shall, upon notice of the designation,
  2  3 similarly designate the prescription drug medication as
  2  4 a schedule II controlled substance.  Such designation by
  2  5 the board shall be immediately effective upon the date
  2  6 of publication in the federal register of the final order
  2  7 designating the prescription drug medication as a schedule II
  2  8 controlled substance.
  2  9    The bill provides that the board shall adopt rules pursuant
  2 10 to Code chapter 17A to administer the bill and may adopt
  2 11 emergency rules which shall be effective immediately upon
  2 12 filing unless a later date is specified in the rules.  Any
  2 13 emergency rules adopted shall also be published as a notice of
  2 14 intended action as provided in Code section 17A.4, subsection
  2 15 1.
  2 16    The bill strikes the repeal of Code chapter 124D (medical
  2 17 cannabidiol Act) before the repeal becomes effective July 1,
  2 18 2017.
       LSB 2301XS (2) 87
       rh/rj
  1 13 as a schedule II controlled substance.
  1 14    b.  The board shall adopt rules pursuant to chapter 17A to
  1 15 administer this subsection.  The board may adopt rules on an
  1 16 emergency basis as provided in section 17A.4, subsection 3, and
  1 17 section 17A.5, subsection 2, to administer this subsection,
  1 18 and the rules shall be effective immediately upon filing
  1 19 unless a later date is specified in the rules.  Any emergency
  1 20 rules adopted in accordance with this subsection shall also be
  1 21 published as a notice of intended action as provided in section
  1 22 17A.4, subsection 1.
  1 23    Sec. 2.  REPEAL.  Section 124D.8, Code 2017, is repealed.
  1 24    Sec. 3.  EFFECTIVE DATE.  The section of this Act repealing
  1 25 section 124D.8, Code 2017, takes effect June 30, 2017.
  1 26                           EXPLANATION
  1 27 The inclusion of this explanation does not constitute agreement with
  1 28 the explanation's substance by the members of the general assembly.
  1 29    This bill relates to the medical use of cannabidiol,
  1 30 including the rescheduling of a cannabidiol investigational
  1 31 product approved as a prescription drug medication under
  1 32 federal law.
  1 33    The bill provides if a cannabidiol investigational product
  1 34 approved as a prescription drug medication by the United States
  1 35 food and drug administration is designated as a schedule II
  2  1 controlled substance by the federal drug enforcement agency,
  2  2 the board of pharmacy shall, upon notice of the designation,
  2  3 similarly designate the prescription drug medication as
  2  4 a schedule II controlled substance.  Such designation by
  2  5 the board shall be immediately effective upon the date
  2  6 of publication in the federal register of the final order
  2  7 designating the prescription drug medication as a schedule II
  2  8 controlled substance.
  2  9    The bill provides that the board shall adopt rules pursuant
  2 10 to Code chapter 17A to administer the bill and may adopt
  2 11 emergency rules which shall be effective immediately upon
  2 12 filing unless a later date is specified in the rules.  Any
  2 13 emergency rules adopted shall also be published as a notice of
  2 14 intended action as provided in Code section 17A.4, subsection
  2 15 1.
  2 16    The bill strikes the repeal of Code chapter 124D (medical
  2 17 cannabidiol Act) before the repeal becomes effective July 1,
  2 18 2017.
       LSB 2301XS (2) 87
       rh/rj
  1 14    b.  The board shall adopt rules pursuant to chapter 17A to
  1 15 administer this subsection.  The board may adopt rules on an
  1 16 emergency basis as provided in section 17A.4, subsection 3, and
  1 17 section 17A.5, subsection 2, to administer this subsection,
  1 18 and the rules shall be effective immediately upon filing
  1 19 unless a later date is specified in the rules.  Any emergency
  1 20 rules adopted in accordance with this subsection shall also be
  1 21 published as a notice of intended action as provided in section
  1 22 17A.4, subsection 1.
  1 23    Sec. 2.  REPEAL.  Section 124D.8, Code 2017, is repealed.
  1 24    Sec. 3.  EFFECTIVE DATE.  The section of this Act repealing
  1 25 section 124D.8, Code 2017, takes effect June 30, 2017.
  1 26                           EXPLANATION
  1 27 The inclusion of this explanation does not constitute agreement with
  1 28 the explanation's substance by the members of the general assembly.
  1 29    This bill relates to the medical use of cannabidiol,
  1 30 including the rescheduling of a cannabidiol investigational
  1 31 product approved as a prescription drug medication under
  1 32 federal law.
  1 33    The bill provides if a cannabidiol investigational product
  1 34 approved as a prescription drug medication by the United States
  1 35 food and drug administration is designated as a schedule II
  2  1 controlled substance by the federal drug enforcement agency,
  2  2 the board of pharmacy shall, upon notice of the designation,
  2  3 similarly designate the prescription drug medication as
  2  4 a schedule II controlled substance.  Such designation by
  2  5 the board shall be immediately effective upon the date
  2  6 of publication in the federal register of the final order
  2  7 designating the prescription drug medication as a schedule II
  2  8 controlled substance.
  2  9    The bill provides that the board shall adopt rules pursuant
  2 10 to Code chapter 17A to administer the bill and may adopt
  2 11 emergency rules which shall be effective immediately upon
  2 12 filing unless a later date is specified in the rules.  Any
  2 13 emergency rules adopted shall also be published as a notice of
  2 14 intended action as provided in Code section 17A.4, subsection
  2 15 1.
  2 16    The bill strikes the repeal of Code chapter 124D (medical
  2 17 cannabidiol Act) before the repeal becomes effective July 1,
  2 18 2017.
       LSB 2301XS (2) 87
       rh/rj
  1 15 administer this subsection.  The board may adopt rules on an
  1 16 emergency basis as provided in section 17A.4, subsection 3, and
  1 17 section 17A.5, subsection 2, to administer this subsection,
  1 18 and the rules shall be effective immediately upon filing
  1 19 unless a later date is specified in the rules.  Any emergency
  1 20 rules adopted in accordance with this subsection shall also be
  1 21 published as a notice of intended action as provided in section
  1 22 17A.4, subsection 1.
  1 23    Sec. 2.  REPEAL.  Section 124D.8, Code 2017, is repealed.
  1 24    Sec. 3.  EFFECTIVE DATE.  The section of this Act repealing
  1 25 section 124D.8, Code 2017, takes effect June 30, 2017.
  1 26                           EXPLANATION
  1 27 The inclusion of this explanation does not constitute agreement with
  1 28 the explanation's substance by the members of the general assembly.
  1 29    This bill relates to the medical use of cannabidiol,
  1 30 including the rescheduling of a cannabidiol investigational
  1 31 product approved as a prescription drug medication under
  1 32 federal law.
  1 33    The bill provides if a cannabidiol investigational product
  1 34 approved as a prescription drug medication by the United States
  1 35 food and drug administration is designated as a schedule II
  2  1 controlled substance by the federal drug enforcement agency,
  2  2 the board of pharmacy shall, upon notice of the designation,
  2  3 similarly designate the prescription drug medication as
  2  4 a schedule II controlled substance.  Such designation by
  2  5 the board shall be immediately effective upon the date
  2  6 of publication in the federal register of the final order
  2  7 designating the prescription drug medication as a schedule II
  2  8 controlled substance.
  2  9    The bill provides that the board shall adopt rules pursuant
  2 10 to Code chapter 17A to administer the bill and may adopt
  2 11 emergency rules which shall be effective immediately upon
  2 12 filing unless a later date is specified in the rules.  Any
  2 13 emergency rules adopted shall also be published as a notice of
  2 14 intended action as provided in Code section 17A.4, subsection
  2 15 1.
  2 16    The bill strikes the repeal of Code chapter 124D (medical
  2 17 cannabidiol Act) before the repeal becomes effective July 1,
  2 18 2017.
       LSB 2301XS (2) 87
       rh/rj
  1 16 emergency basis as provided in section 17A.4, subsection 3, and
  1 17 section 17A.5, subsection 2, to administer this subsection,
  1 18 and the rules shall be effective immediately upon filing
  1 19 unless a later date is specified in the rules.  Any emergency
  1 20 rules adopted in accordance with this subsection shall also be
  1 21 published as a notice of intended action as provided in section
  1 22 17A.4, subsection 1.
  1 23    Sec. 2.  REPEAL.  Section 124D.8, Code 2017, is repealed.
  1 24    Sec. 3.  EFFECTIVE DATE.  The section of this Act repealing
  1 25 section 124D.8, Code 2017, takes effect June 30, 2017.
  1 26                           EXPLANATION
  1 27 The inclusion of this explanation does not constitute agreement with
  1 28 the explanation's substance by the members of the general assembly.
  1 29    This bill relates to the medical use of cannabidiol,
  1 30 including the rescheduling of a cannabidiol investigational
  1 31 product approved as a prescription drug medication under
  1 32 federal law.
  1 33    The bill provides if a cannabidiol investigational product
  1 34 approved as a prescription drug medication by the United States
  1 35 food and drug administration is designated as a schedule II
  2  1 controlled substance by the federal drug enforcement agency,
  2  2 the board of pharmacy shall, upon notice of the designation,
  2  3 similarly designate the prescription drug medication as
  2  4 a schedule II controlled substance.  Such designation by
  2  5 the board shall be immediately effective upon the date
  2  6 of publication in the federal register of the final order
  2  7 designating the prescription drug medication as a schedule II
  2  8 controlled substance.
  2  9    The bill provides that the board shall adopt rules pursuant
  2 10 to Code chapter 17A to administer the bill and may adopt
  2 11 emergency rules which shall be effective immediately upon
  2 12 filing unless a later date is specified in the rules.  Any
  2 13 emergency rules adopted shall also be published as a notice of
  2 14 intended action as provided in Code section 17A.4, subsection
  2 15 1.
  2 16    The bill strikes the repeal of Code chapter 124D (medical
  2 17 cannabidiol Act) before the repeal becomes effective July 1,
  2 18 2017.
       LSB 2301XS (2) 87
       rh/rj
  1 17 section 17A.5, subsection 2, to administer this subsection,
  1 18 and the rules shall be effective immediately upon filing
  1 19 unless a later date is specified in the rules.  Any emergency
  1 20 rules adopted in accordance with this subsection shall also be
  1 21 published as a notice of intended action as provided in section
  1 22 17A.4, subsection 1.
  1 23    Sec. 2.  REPEAL.  Section 124D.8, Code 2017, is repealed.
  1 24    Sec. 3.  EFFECTIVE DATE.  The section of this Act repealing
  1 25 section 124D.8, Code 2017, takes effect June 30, 2017.
  1 26                           EXPLANATION
  1 27 The inclusion of this explanation does not constitute agreement with
  1 28 the explanation's substance by the members of the general assembly.
  1 29    This bill relates to the medical use of cannabidiol,
  1 30 including the rescheduling of a cannabidiol investigational
  1 31 product approved as a prescription drug medication under
  1 32 federal law.
  1 33    The bill provides if a cannabidiol investigational product
  1 34 approved as a prescription drug medication by the United States
  1 35 food and drug administration is designated as a schedule II
  2  1 controlled substance by the federal drug enforcement agency,
  2  2 the board of pharmacy shall, upon notice of the designation,
  2  3 similarly designate the prescription drug medication as
  2  4 a schedule II controlled substance.  Such designation by
  2  5 the board shall be immediately effective upon the date
  2  6 of publication in the federal register of the final order
  2  7 designating the prescription drug medication as a schedule II
  2  8 controlled substance.
  2  9    The bill provides that the board shall adopt rules pursuant
  2 10 to Code chapter 17A to administer the bill and may adopt
  2 11 emergency rules which shall be effective immediately upon
  2 12 filing unless a later date is specified in the rules.  Any
  2 13 emergency rules adopted shall also be published as a notice of
  2 14 intended action as provided in Code section 17A.4, subsection
  2 15 1.
  2 16    The bill strikes the repeal of Code chapter 124D (medical
  2 17 cannabidiol Act) before the repeal becomes effective July 1,
  2 18 2017.
       LSB 2301XS (2) 87
       rh/rj
  1 18 and the rules shall be effective immediately upon filing
  1 19 unless a later date is specified in the rules.  Any emergency
  1 20 rules adopted in accordance with this subsection shall also be
  1 21 published as a notice of intended action as provided in section
  1 22 17A.4, subsection 1.
  1 23    Sec. 2.  REPEAL.  Section 124D.8, Code 2017, is repealed.
  1 24    Sec. 3.  EFFECTIVE DATE.  The section of this Act repealing
  1 25 section 124D.8, Code 2017, takes effect June 30, 2017.
  1 26                           EXPLANATION
  1 27 The inclusion of this explanation does not constitute agreement with
  1 28 the explanation's substance by the members of the general assembly.
  1 29    This bill relates to the medical use of cannabidiol,
  1 30 including the rescheduling of a cannabidiol investigational
  1 31 product approved as a prescription drug medication under
  1 32 federal law.
  1 33    The bill provides if a cannabidiol investigational product
  1 34 approved as a prescription drug medication by the United States
  1 35 food and drug administration is designated as a schedule II
  2  1 controlled substance by the federal drug enforcement agency,
  2  2 the board of pharmacy shall, upon notice of the designation,
  2  3 similarly designate the prescription drug medication as
  2  4 a schedule II controlled substance.  Such designation by
  2  5 the board shall be immediately effective upon the date
  2  6 of publication in the federal register of the final order
  2  7 designating the prescription drug medication as a schedule II
  2  8 controlled substance.
  2  9    The bill provides that the board shall adopt rules pursuant
  2 10 to Code chapter 17A to administer the bill and may adopt
  2 11 emergency rules which shall be effective immediately upon
  2 12 filing unless a later date is specified in the rules.  Any
  2 13 emergency rules adopted shall also be published as a notice of
  2 14 intended action as provided in Code section 17A.4, subsection
  2 15 1.
  2 16    The bill strikes the repeal of Code chapter 124D (medical
  2 17 cannabidiol Act) before the repeal becomes effective July 1,
  2 18 2017.
       LSB 2301XS (2) 87
       rh/rj
  1 19 unless a later date is specified in the rules.  Any emergency
  1 20 rules adopted in accordance with this subsection shall also be
  1 21 published as a notice of intended action as provided in section
  1 22 17A.4, subsection 1.
  1 23    Sec. 2.  REPEAL.  Section 124D.8, Code 2017, is repealed.
  1 24    Sec. 3.  EFFECTIVE DATE.  The section of this Act repealing
  1 25 section 124D.8, Code 2017, takes effect June 30, 2017.
  1 26                           EXPLANATION
  1 27 The inclusion of this explanation does not constitute agreement with
  1 28 the explanation's substance by the members of the general assembly.
  1 29    This bill relates to the medical use of cannabidiol,
  1 30 including the rescheduling of a cannabidiol investigational
  1 31 product approved as a prescription drug medication under
  1 32 federal law.
  1 33    The bill provides if a cannabidiol investigational product
  1 34 approved as a prescription drug medication by the United States
  1 35 food and drug administration is designated as a schedule II
  2  1 controlled substance by the federal drug enforcement agency,
  2  2 the board of pharmacy shall, upon notice of the designation,
  2  3 similarly designate the prescription drug medication as
  2  4 a schedule II controlled substance.  Such designation by
  2  5 the board shall be immediately effective upon the date
  2  6 of publication in the federal register of the final order
  2  7 designating the prescription drug medication as a schedule II
  2  8 controlled substance.
  2  9    The bill provides that the board shall adopt rules pursuant
  2 10 to Code chapter 17A to administer the bill and may adopt
  2 11 emergency rules which shall be effective immediately upon
  2 12 filing unless a later date is specified in the rules.  Any
  2 13 emergency rules adopted shall also be published as a notice of
  2 14 intended action as provided in Code section 17A.4, subsection
  2 15 1.
  2 16    The bill strikes the repeal of Code chapter 124D (medical
  2 17 cannabidiol Act) before the repeal becomes effective July 1,
  2 18 2017.
       LSB 2301XS (2) 87
       rh/rj
  1 20 rules adopted in accordance with this subsection shall also be
  1 21 published as a notice of intended action as provided in section
  1 22 17A.4, subsection 1.
  1 23    Sec. 2.  REPEAL.  Section 124D.8, Code 2017, is repealed.
  1 24    Sec. 3.  EFFECTIVE DATE.  The section of this Act repealing
  1 25 section 124D.8, Code 2017, takes effect June 30, 2017.
  1 26                           EXPLANATION
  1 27 The inclusion of this explanation does not constitute agreement with
  1 28 the explanation's substance by the members of the general assembly.
  1 29    This bill relates to the medical use of cannabidiol,
  1 30 including the rescheduling of a cannabidiol investigational
  1 31 product approved as a prescription drug medication under
  1 32 federal law.
  1 33    The bill provides if a cannabidiol investigational product
  1 34 approved as a prescription drug medication by the United States
  1 35 food and drug administration is designated as a schedule II
  2  1 controlled substance by the federal drug enforcement agency,
  2  2 the board of pharmacy shall, upon notice of the designation,
  2  3 similarly designate the prescription drug medication as
  2  4 a schedule II controlled substance.  Such designation by
  2  5 the board shall be immediately effective upon the date
  2  6 of publication in the federal register of the final order
  2  7 designating the prescription drug medication as a schedule II
  2  8 controlled substance.
  2  9    The bill provides that the board shall adopt rules pursuant
  2 10 to Code chapter 17A to administer the bill and may adopt
  2 11 emergency rules which shall be effective immediately upon
  2 12 filing unless a later date is specified in the rules.  Any
  2 13 emergency rules adopted shall also be published as a notice of
  2 14 intended action as provided in Code section 17A.4, subsection
  2 15 1.
  2 16    The bill strikes the repeal of Code chapter 124D (medical
  2 17 cannabidiol Act) before the repeal becomes effective July 1,
  2 18 2017.
       LSB 2301XS (2) 87
       rh/rj
  1 21 published as a notice of intended action as provided in section
  1 22 17A.4, subsection 1.
  1 23    Sec. 2.  REPEAL.  Section 124D.8, Code 2017, is repealed.
  1 24    Sec. 3.  EFFECTIVE DATE.  The section of this Act repealing
  1 25 section 124D.8, Code 2017, takes effect June 30, 2017.
  1 26                           EXPLANATION
  1 27 The inclusion of this explanation does not constitute agreement with
  1 28 the explanation's substance by the members of the general assembly.
  1 29    This bill relates to the medical use of cannabidiol,
  1 30 including the rescheduling of a cannabidiol investigational
  1 31 product approved as a prescription drug medication under
  1 32 federal law.
  1 33    The bill provides if a cannabidiol investigational product
  1 34 approved as a prescription drug medication by the United States
  1 35 food and drug administration is designated as a schedule II
  2  1 controlled substance by the federal drug enforcement agency,
  2  2 the board of pharmacy shall, upon notice of the designation,
  2  3 similarly designate the prescription drug medication as
  2  4 a schedule II controlled substance.  Such designation by
  2  5 the board shall be immediately effective upon the date
  2  6 of publication in the federal register of the final order
  2  7 designating the prescription drug medication as a schedule II
  2  8 controlled substance.
  2  9    The bill provides that the board shall adopt rules pursuant
  2 10 to Code chapter 17A to administer the bill and may adopt
  2 11 emergency rules which shall be effective immediately upon
  2 12 filing unless a later date is specified in the rules.  Any
  2 13 emergency rules adopted shall also be published as a notice of
  2 14 intended action as provided in Code section 17A.4, subsection
  2 15 1.
  2 16    The bill strikes the repeal of Code chapter 124D (medical
  2 17 cannabidiol Act) before the repeal becomes effective July 1,
  2 18 2017.
       LSB 2301XS (2) 87
       rh/rj
  1 22 17A.4, subsection 1.
  1 23    Sec. 2.  REPEAL.  Section 124D.8, Code 2017, is repealed.
  1 24    Sec. 3.  EFFECTIVE DATE.  The section of this Act repealing
  1 25 section 124D.8, Code 2017, takes effect June 30, 2017.
  1 26                           EXPLANATION
  1 27 The inclusion of this explanation does not constitute agreement with
  1 28 the explanation's substance by the members of the general assembly.
  1 29    This bill relates to the medical use of cannabidiol,
  1 30 including the rescheduling of a cannabidiol investigational
  1 31 product approved as a prescription drug medication under
  1 32 federal law.
  1 33    The bill provides if a cannabidiol investigational product
  1 34 approved as a prescription drug medication by the United States
  1 35 food and drug administration is designated as a schedule II
  2  1 controlled substance by the federal drug enforcement agency,
  2  2 the board of pharmacy shall, upon notice of the designation,
  2  3 similarly designate the prescription drug medication as
  2  4 a schedule II controlled substance.  Such designation by
  2  5 the board shall be immediately effective upon the date
  2  6 of publication in the federal register of the final order
  2  7 designating the prescription drug medication as a schedule II
  2  8 controlled substance.
  2  9    The bill provides that the board shall adopt rules pursuant
  2 10 to Code chapter 17A to administer the bill and may adopt
  2 11 emergency rules which shall be effective immediately upon
  2 12 filing unless a later date is specified in the rules.  Any
  2 13 emergency rules adopted shall also be published as a notice of
  2 14 intended action as provided in Code section 17A.4, subsection
  2 15 1.
  2 16    The bill strikes the repeal of Code chapter 124D (medical
  2 17 cannabidiol Act) before the repeal becomes effective July 1,
  2 18 2017.
       LSB 2301XS (2) 87
       rh/rj
  1 23    Sec. 2.  REPEAL.  Section 124D.8, Code 2017, is repealed.
  1 24    Sec. 3.  EFFECTIVE DATE.  The section of this Act repealing
  1 25 section 124D.8, Code 2017, takes effect June 30, 2017.
  1 26                           EXPLANATION
  1 27 The inclusion of this explanation does not constitute agreement with
  1 28 the explanation's substance by the members of the general assembly.
  1 29    This bill relates to the medical use of cannabidiol,
  1 30 including the rescheduling of a cannabidiol investigational
  1 31 product approved as a prescription drug medication under
  1 32 federal law.
  1 33    The bill provides if a cannabidiol investigational product
  1 34 approved as a prescription drug medication by the United States
  1 35 food and drug administration is designated as a schedule II
  2  1 controlled substance by the federal drug enforcement agency,
  2  2 the board of pharmacy shall, upon notice of the designation,
  2  3 similarly designate the prescription drug medication as
  2  4 a schedule II controlled substance.  Such designation by
  2  5 the board shall be immediately effective upon the date
  2  6 of publication in the federal register of the final order
  2  7 designating the prescription drug medication as a schedule II
  2  8 controlled substance.
  2  9    The bill provides that the board shall adopt rules pursuant
  2 10 to Code chapter 17A to administer the bill and may adopt
  2 11 emergency rules which shall be effective immediately upon
  2 12 filing unless a later date is specified in the rules.  Any
  2 13 emergency rules adopted shall also be published as a notice of
  2 14 intended action as provided in Code section 17A.4, subsection
  2 15 1.
  2 16    The bill strikes the repeal of Code chapter 124D (medical
  2 17 cannabidiol Act) before the repeal becomes effective July 1,
  2 18 2017.
       LSB 2301XS (2) 87
       rh/rj
  1 24    Sec. 3.  EFFECTIVE DATE.  The section of this Act repealing
  1 25 section 124D.8, Code 2017, takes effect June 30, 2017.
  1 26                           EXPLANATION
  1 27 The inclusion of this explanation does not constitute agreement with
  1 28 the explanation's substance by the members of the general assembly.
  1 29    This bill relates to the medical use of cannabidiol,
  1 30 including the rescheduling of a cannabidiol investigational
  1 31 product approved as a prescription drug medication under
  1 32 federal law.
  1 33    The bill provides if a cannabidiol investigational product
  1 34 approved as a prescription drug medication by the United States
  1 35 food and drug administration is designated as a schedule II
  2  1 controlled substance by the federal drug enforcement agency,
  2  2 the board of pharmacy shall, upon notice of the designation,
  2  3 similarly designate the prescription drug medication as
  2  4 a schedule II controlled substance.  Such designation by
  2  5 the board shall be immediately effective upon the date
  2  6 of publication in the federal register of the final order
  2  7 designating the prescription drug medication as a schedule II
  2  8 controlled substance.
  2  9    The bill provides that the board shall adopt rules pursuant
  2 10 to Code chapter 17A to administer the bill and may adopt
  2 11 emergency rules which shall be effective immediately upon
  2 12 filing unless a later date is specified in the rules.  Any
  2 13 emergency rules adopted shall also be published as a notice of
  2 14 intended action as provided in Code section 17A.4, subsection
  2 15 1.
  2 16    The bill strikes the repeal of Code chapter 124D (medical
  2 17 cannabidiol Act) before the repeal becomes effective July 1,
  2 18 2017.
       LSB 2301XS (2) 87
       rh/rj
  1 25 section 124D.8, Code 2017, takes effect June 30, 2017.
  1 26                           EXPLANATION
  1 27 The inclusion of this explanation does not constitute agreement with
  1 28 the explanation's substance by the members of the general assembly.
  1 29    This bill relates to the medical use of cannabidiol,
  1 30 including the rescheduling of a cannabidiol investigational
  1 31 product approved as a prescription drug medication under
  1 32 federal law.
  1 33    The bill provides if a cannabidiol investigational product
  1 34 approved as a prescription drug medication by the United States
  1 35 food and drug administration is designated as a schedule II
  2  1 controlled substance by the federal drug enforcement agency,
  2  2 the board of pharmacy shall, upon notice of the designation,
  2  3 similarly designate the prescription drug medication as
  2  4 a schedule II controlled substance.  Such designation by
  2  5 the board shall be immediately effective upon the date
  2  6 of publication in the federal register of the final order
  2  7 designating the prescription drug medication as a schedule II
  2  8 controlled substance.
  2  9    The bill provides that the board shall adopt rules pursuant
  2 10 to Code chapter 17A to administer the bill and may adopt
  2 11 emergency rules which shall be effective immediately upon
  2 12 filing unless a later date is specified in the rules.  Any
  2 13 emergency rules adopted shall also be published as a notice of
  2 14 intended action as provided in Code section 17A.4, subsection
  2 15 1.
  2 16    The bill strikes the repeal of Code chapter 124D (medical
  2 17 cannabidiol Act) before the repeal becomes effective July 1,
  2 18 2017.
       LSB 2301XS (2) 87
       rh/rj
  1 26                           EXPLANATION
  1 27 The inclusion of this explanation does not constitute agreement with
  1 28 the explanation's substance by the members of the general assembly.
  1 29    This bill relates to the medical use of cannabidiol,
  1 30 including the rescheduling of a cannabidiol investigational
  1 31 product approved as a prescription drug medication under
  1 32 federal law.
  1 33    The bill provides if a cannabidiol investigational product
  1 34 approved as a prescription drug medication by the United States
  1 35 food and drug administration is designated as a schedule II
  2  1 controlled substance by the federal drug enforcement agency,
  2  2 the board of pharmacy shall, upon notice of the designation,
  2  3 similarly designate the prescription drug medication as
  2  4 a schedule II controlled substance.  Such designation by
  2  5 the board shall be immediately effective upon the date
  2  6 of publication in the federal register of the final order
  2  7 designating the prescription drug medication as a schedule II
  2  8 controlled substance.
  2  9    The bill provides that the board shall adopt rules pursuant
  2 10 to Code chapter 17A to administer the bill and may adopt
  2 11 emergency rules which shall be effective immediately upon
  2 12 filing unless a later date is specified in the rules.  Any
  2 13 emergency rules adopted shall also be published as a notice of
  2 14 intended action as provided in Code section 17A.4, subsection
  2 15 1.
  2 16    The bill strikes the repeal of Code chapter 124D (medical
  2 17 cannabidiol Act) before the repeal becomes effective July 1,
  2 18 2017.
       LSB 2301XS (2) 87
       rh/rj
  1 27 The inclusion of this explanation does not constitute agreement with
  1 28 the explanation's substance by the members of the general assembly.
  1 29    This bill relates to the medical use of cannabidiol,
  1 30 including the rescheduling of a cannabidiol investigational
  1 31 product approved as a prescription drug medication under
  1 32 federal law.
  1 33    The bill provides if a cannabidiol investigational product
  1 34 approved as a prescription drug medication by the United States
  1 35 food and drug administration is designated as a schedule II
  2  1 controlled substance by the federal drug enforcement agency,
  2  2 the board of pharmacy shall, upon notice of the designation,
  2  3 similarly designate the prescription drug medication as
  2  4 a schedule II controlled substance.  Such designation by
  2  5 the board shall be immediately effective upon the date
  2  6 of publication in the federal register of the final order
  2  7 designating the prescription drug medication as a schedule II
  2  8 controlled substance.
  2  9    The bill provides that the board shall adopt rules pursuant
  2 10 to Code chapter 17A to administer the bill and may adopt
  2 11 emergency rules which shall be effective immediately upon
  2 12 filing unless a later date is specified in the rules.  Any
  2 13 emergency rules adopted shall also be published as a notice of
  2 14 intended action as provided in Code section 17A.4, subsection
  2 15 1.
  2 16    The bill strikes the repeal of Code chapter 124D (medical
  2 17 cannabidiol Act) before the repeal becomes effective July 1,
  2 18 2017.
       LSB 2301XS (2) 87
       rh/rj
  1 28 the explanation's substance by the members of the general assembly.
  1 29    This bill relates to the medical use of cannabidiol,
  1 30 including the rescheduling of a cannabidiol investigational
  1 31 product approved as a prescription drug medication under
  1 32 federal law.
  1 33    The bill provides if a cannabidiol investigational product
  1 34 approved as a prescription drug medication by the United States
  1 35 food and drug administration is designated as a schedule II
  2  1 controlled substance by the federal drug enforcement agency,
  2  2 the board of pharmacy shall, upon notice of the designation,
  2  3 similarly designate the prescription drug medication as
  2  4 a schedule II controlled substance.  Such designation by
  2  5 the board shall be immediately effective upon the date
  2  6 of publication in the federal register of the final order
  2  7 designating the prescription drug medication as a schedule II
  2  8 controlled substance.
  2  9    The bill provides that the board shall adopt rules pursuant
  2 10 to Code chapter 17A to administer the bill and may adopt
  2 11 emergency rules which shall be effective immediately upon
  2 12 filing unless a later date is specified in the rules.  Any
  2 13 emergency rules adopted shall also be published as a notice of
  2 14 intended action as provided in Code section 17A.4, subsection
  2 15 1.
  2 16    The bill strikes the repeal of Code chapter 124D (medical
  2 17 cannabidiol Act) before the repeal becomes effective July 1,
  2 18 2017.
       LSB 2301XS (2) 87
       rh/rj
  1 29    This bill relates to the medical use of cannabidiol,
  1 30 including the rescheduling of a cannabidiol investigational
  1 31 product approved as a prescription drug medication under
  1 32 federal law.
  1 33    The bill provides if a cannabidiol investigational product
  1 34 approved as a prescription drug medication by the United States
  1 35 food and drug administration is designated as a schedule II
  2  1 controlled substance by the federal drug enforcement agency,
  2  2 the board of pharmacy shall, upon notice of the designation,
  2  3 similarly designate the prescription drug medication as
  2  4 a schedule II controlled substance.  Such designation by
  2  5 the board shall be immediately effective upon the date
  2  6 of publication in the federal register of the final order
  2  7 designating the prescription drug medication as a schedule II
  2  8 controlled substance.
  2  9    The bill provides that the board shall adopt rules pursuant
  2 10 to Code chapter 17A to administer the bill and may adopt
  2 11 emergency rules which shall be effective immediately upon
  2 12 filing unless a later date is specified in the rules.  Any
  2 13 emergency rules adopted shall also be published as a notice of
  2 14 intended action as provided in Code section 17A.4, subsection
  2 15 1.
  2 16    The bill strikes the repeal of Code chapter 124D (medical
  2 17 cannabidiol Act) before the repeal becomes effective July 1,
  2 18 2017.
       LSB 2301XS (2) 87
       rh/rj
  1 30 including the rescheduling of a cannabidiol investigational
  1 31 product approved as a prescription drug medication under
  1 32 federal law.
  1 33    The bill provides if a cannabidiol investigational product
  1 34 approved as a prescription drug medication by the United States
  1 35 food and drug administration is designated as a schedule II
  2  1 controlled substance by the federal drug enforcement agency,
  2  2 the board of pharmacy shall, upon notice of the designation,
  2  3 similarly designate the prescription drug medication as
  2  4 a schedule II controlled substance.  Such designation by
  2  5 the board shall be immediately effective upon the date
  2  6 of publication in the federal register of the final order
  2  7 designating the prescription drug medication as a schedule II
  2  8 controlled substance.
  2  9    The bill provides that the board shall adopt rules pursuant
  2 10 to Code chapter 17A to administer the bill and may adopt
  2 11 emergency rules which shall be effective immediately upon
  2 12 filing unless a later date is specified in the rules.  Any
  2 13 emergency rules adopted shall also be published as a notice of
  2 14 intended action as provided in Code section 17A.4, subsection
  2 15 1.
  2 16    The bill strikes the repeal of Code chapter 124D (medical
  2 17 cannabidiol Act) before the repeal becomes effective July 1,
  2 18 2017.
       LSB 2301XS (2) 87
       rh/rj
  1 31 product approved as a prescription drug medication under
  1 32 federal law.
  1 33    The bill provides if a cannabidiol investigational product
  1 34 approved as a prescription drug medication by the United States
  1 35 food and drug administration is designated as a schedule II
  2  1 controlled substance by the federal drug enforcement agency,
  2  2 the board of pharmacy shall, upon notice of the designation,
  2  3 similarly designate the prescription drug medication as
  2  4 a schedule II controlled substance.  Such designation by
  2  5 the board shall be immediately effective upon the date
  2  6 of publication in the federal register of the final order
  2  7 designating the prescription drug medication as a schedule II
  2  8 controlled substance.
  2  9    The bill provides that the board shall adopt rules pursuant
  2 10 to Code chapter 17A to administer the bill and may adopt
  2 11 emergency rules which shall be effective immediately upon
  2 12 filing unless a later date is specified in the rules.  Any
  2 13 emergency rules adopted shall also be published as a notice of
  2 14 intended action as provided in Code section 17A.4, subsection
  2 15 1.
  2 16    The bill strikes the repeal of Code chapter 124D (medical
  2 17 cannabidiol Act) before the repeal becomes effective July 1,
  2 18 2017.
       LSB 2301XS (2) 87
       rh/rj
  1 32 federal law.
  1 33    The bill provides if a cannabidiol investigational product
  1 34 approved as a prescription drug medication by the United States
  1 35 food and drug administration is designated as a schedule II
  2  1 controlled substance by the federal drug enforcement agency,
  2  2 the board of pharmacy shall, upon notice of the designation,
  2  3 similarly designate the prescription drug medication as
  2  4 a schedule II controlled substance.  Such designation by
  2  5 the board shall be immediately effective upon the date
  2  6 of publication in the federal register of the final order
  2  7 designating the prescription drug medication as a schedule II
  2  8 controlled substance.
  2  9    The bill provides that the board shall adopt rules pursuant
  2 10 to Code chapter 17A to administer the bill and may adopt
  2 11 emergency rules which shall be effective immediately upon
  2 12 filing unless a later date is specified in the rules.  Any
  2 13 emergency rules adopted shall also be published as a notice of
  2 14 intended action as provided in Code section 17A.4, subsection
  2 15 1.
  2 16    The bill strikes the repeal of Code chapter 124D (medical
  2 17 cannabidiol Act) before the repeal becomes effective July 1,
  2 18 2017.
       LSB 2301XS (2) 87
       rh/rj
  1 33    The bill provides if a cannabidiol investigational product
  1 34 approved as a prescription drug medication by the United States
  1 35 food and drug administration is designated as a schedule II
  2  1 controlled substance by the federal drug enforcement agency,
  2  2 the board of pharmacy shall, upon notice of the designation,
  2  3 similarly designate the prescription drug medication as
  2  4 a schedule II controlled substance.  Such designation by
  2  5 the board shall be immediately effective upon the date
  2  6 of publication in the federal register of the final order
  2  7 designating the prescription drug medication as a schedule II
  2  8 controlled substance.
  2  9    The bill provides that the board shall adopt rules pursuant
  2 10 to Code chapter 17A to administer the bill and may adopt
  2 11 emergency rules which shall be effective immediately upon
  2 12 filing unless a later date is specified in the rules.  Any
  2 13 emergency rules adopted shall also be published as a notice of
  2 14 intended action as provided in Code section 17A.4, subsection
  2 15 1.
  2 16    The bill strikes the repeal of Code chapter 124D (medical
  2 17 cannabidiol Act) before the repeal becomes effective July 1,
  2 18 2017.
       LSB 2301XS (2) 87
       rh/rj
  1 34 approved as a prescription drug medication by the United States
  1 35 food and drug administration is designated as a schedule II
  2  1 controlled substance by the federal drug enforcement agency,
  2  2 the board of pharmacy shall, upon notice of the designation,
  2  3 similarly designate the prescription drug medication as
  2  4 a schedule II controlled substance.  Such designation by
  2  5 the board shall be immediately effective upon the date
  2  6 of publication in the federal register of the final order
  2  7 designating the prescription drug medication as a schedule II
  2  8 controlled substance.
  2  9    The bill provides that the board shall adopt rules pursuant
  2 10 to Code chapter 17A to administer the bill and may adopt
  2 11 emergency rules which shall be effective immediately upon
  2 12 filing unless a later date is specified in the rules.  Any
  2 13 emergency rules adopted shall also be published as a notice of
  2 14 intended action as provided in Code section 17A.4, subsection
  2 15 1.
  2 16    The bill strikes the repeal of Code chapter 124D (medical
  2 17 cannabidiol Act) before the repeal becomes effective July 1,
  2 18 2017.
       LSB 2301XS (2) 87
       rh/rj
  1 35 food and drug administration is designated as a schedule II
  2  1 controlled substance by the federal drug enforcement agency,
  2  2 the board of pharmacy shall, upon notice of the designation,
  2  3 similarly designate the prescription drug medication as
  2  4 a schedule II controlled substance.  Such designation by
  2  5 the board shall be immediately effective upon the date
  2  6 of publication in the federal register of the final order
  2  7 designating the prescription drug medication as a schedule II
  2  8 controlled substance.
  2  9    The bill provides that the board shall adopt rules pursuant
  2 10 to Code chapter 17A to administer the bill and may adopt
  2 11 emergency rules which shall be effective immediately upon
  2 12 filing unless a later date is specified in the rules.  Any
  2 13 emergency rules adopted shall also be published as a notice of
  2 14 intended action as provided in Code section 17A.4, subsection
  2 15 1.
  2 16    The bill strikes the repeal of Code chapter 124D (medical
  2 17 cannabidiol Act) before the repeal becomes effective July 1,
  2 18 2017.
       LSB 2301XS (2) 87
       rh/rj
  2  1 controlled substance by the federal drug enforcement agency,
  2  2 the board of pharmacy shall, upon notice of the designation,
  2  3 similarly designate the prescription drug medication as
  2  4 a schedule II controlled substance.  Such designation by
  2  5 the board shall be immediately effective upon the date
  2  6 of publication in the federal register of the final order
  2  7 designating the prescription drug medication as a schedule II
  2  8 controlled substance.
  2  9    The bill provides that the board shall adopt rules pursuant
  2 10 to Code chapter 17A to administer the bill and may adopt
  2 11 emergency rules which shall be effective immediately upon
  2 12 filing unless a later date is specified in the rules.  Any
  2 13 emergency rules adopted shall also be published as a notice of
  2 14 intended action as provided in Code section 17A.4, subsection
  2 15 1.
  2 16    The bill strikes the repeal of Code chapter 124D (medical
  2 17 cannabidiol Act) before the repeal becomes effective July 1,
  2 18 2017.
       LSB 2301XS (2) 87
       rh/rj
  2  2 the board of pharmacy shall, upon notice of the designation,
  2  3 similarly designate the prescription drug medication as
  2  4 a schedule II controlled substance.  Such designation by
  2  5 the board shall be immediately effective upon the date
  2  6 of publication in the federal register of the final order
  2  7 designating the prescription drug medication as a schedule II
  2  8 controlled substance.
  2  9    The bill provides that the board shall adopt rules pursuant
  2 10 to Code chapter 17A to administer the bill and may adopt
  2 11 emergency rules which shall be effective immediately upon
  2 12 filing unless a later date is specified in the rules.  Any
  2 13 emergency rules adopted shall also be published as a notice of
  2 14 intended action as provided in Code section 17A.4, subsection
  2 15 1.
  2 16    The bill strikes the repeal of Code chapter 124D (medical
  2 17 cannabidiol Act) before the repeal becomes effective July 1,
  2 18 2017.
       LSB 2301XS (2) 87
       rh/rj
  2  3 similarly designate the prescription drug medication as
  2  4 a schedule II controlled substance.  Such designation by
  2  5 the board shall be immediately effective upon the date
  2  6 of publication in the federal register of the final order
  2  7 designating the prescription drug medication as a schedule II
  2  8 controlled substance.
  2  9    The bill provides that the board shall adopt rules pursuant
  2 10 to Code chapter 17A to administer the bill and may adopt
  2 11 emergency rules which shall be effective immediately upon
  2 12 filing unless a later date is specified in the rules.  Any
  2 13 emergency rules adopted shall also be published as a notice of
  2 14 intended action as provided in Code section 17A.4, subsection
  2 15 1.
  2 16    The bill strikes the repeal of Code chapter 124D (medical
  2 17 cannabidiol Act) before the repeal becomes effective July 1,
  2 18 2017.
       LSB 2301XS (2) 87
       rh/rj
  2  4 a schedule II controlled substance.  Such designation by
  2  5 the board shall be immediately effective upon the date
  2  6 of publication in the federal register of the final order
  2  7 designating the prescription drug medication as a schedule II
  2  8 controlled substance.
  2  9    The bill provides that the board shall adopt rules pursuant
  2 10 to Code chapter 17A to administer the bill and may adopt
  2 11 emergency rules which shall be effective immediately upon
  2 12 filing unless a later date is specified in the rules.  Any
  2 13 emergency rules adopted shall also be published as a notice of
  2 14 intended action as provided in Code section 17A.4, subsection
  2 15 1.
  2 16    The bill strikes the repeal of Code chapter 124D (medical
  2 17 cannabidiol Act) before the repeal becomes effective July 1,
  2 18 2017.
       LSB 2301XS (2) 87
       rh/rj
  2  5 the board shall be immediately effective upon the date
  2  6 of publication in the federal register of the final order
  2  7 designating the prescription drug medication as a schedule II
  2  8 controlled substance.
  2  9    The bill provides that the board shall adopt rules pursuant
  2 10 to Code chapter 17A to administer the bill and may adopt
  2 11 emergency rules which shall be effective immediately upon
  2 12 filing unless a later date is specified in the rules.  Any
  2 13 emergency rules adopted shall also be published as a notice of
  2 14 intended action as provided in Code section 17A.4, subsection
  2 15 1.
  2 16    The bill strikes the repeal of Code chapter 124D (medical
  2 17 cannabidiol Act) before the repeal becomes effective July 1,
  2 18 2017.
       LSB 2301XS (2) 87
       rh/rj
  2  6 of publication in the federal register of the final order
  2  7 designating the prescription drug medication as a schedule II
  2  8 controlled substance.
  2  9    The bill provides that the board shall adopt rules pursuant
  2 10 to Code chapter 17A to administer the bill and may adopt
  2 11 emergency rules which shall be effective immediately upon
  2 12 filing unless a later date is specified in the rules.  Any
  2 13 emergency rules adopted shall also be published as a notice of
  2 14 intended action as provided in Code section 17A.4, subsection
  2 15 1.
  2 16    The bill strikes the repeal of Code chapter 124D (medical
  2 17 cannabidiol Act) before the repeal becomes effective July 1,
  2 18 2017.
       LSB 2301XS (2) 87
       rh/rj
  2  7 designating the prescription drug medication as a schedule II
  2  8 controlled substance.
  2  9    The bill provides that the board shall adopt rules pursuant
  2 10 to Code chapter 17A to administer the bill and may adopt
  2 11 emergency rules which shall be effective immediately upon
  2 12 filing unless a later date is specified in the rules.  Any
  2 13 emergency rules adopted shall also be published as a notice of
  2 14 intended action as provided in Code section 17A.4, subsection
  2 15 1.
  2 16    The bill strikes the repeal of Code chapter 124D (medical
  2 17 cannabidiol Act) before the repeal becomes effective July 1,
  2 18 2017.
       LSB 2301XS (2) 87
       rh/rj
  2  8 controlled substance.
  2  9    The bill provides that the board shall adopt rules pursuant
  2 10 to Code chapter 17A to administer the bill and may adopt
  2 11 emergency rules which shall be effective immediately upon
  2 12 filing unless a later date is specified in the rules.  Any
  2 13 emergency rules adopted shall also be published as a notice of
  2 14 intended action as provided in Code section 17A.4, subsection
  2 15 1.
  2 16    The bill strikes the repeal of Code chapter 124D (medical
  2 17 cannabidiol Act) before the repeal becomes effective July 1,
  2 18 2017.
       LSB 2301XS (2) 87
       rh/rj
  2  9    The bill provides that the board shall adopt rules pursuant
  2 10 to Code chapter 17A to administer the bill and may adopt
  2 11 emergency rules which shall be effective immediately upon
  2 12 filing unless a later date is specified in the rules.  Any
  2 13 emergency rules adopted shall also be published as a notice of
  2 14 intended action as provided in Code section 17A.4, subsection
  2 15 1.
  2 16    The bill strikes the repeal of Code chapter 124D (medical
  2 17 cannabidiol Act) before the repeal becomes effective July 1,
  2 18 2017.
       LSB 2301XS (2) 87
       rh/rj
  2 10 to Code chapter 17A to administer the bill and may adopt
  2 11 emergency rules which shall be effective immediately upon
  2 12 filing unless a later date is specified in the rules.  Any
  2 13 emergency rules adopted shall also be published as a notice of
  2 14 intended action as provided in Code section 17A.4, subsection
  2 15 1.
  2 16    The bill strikes the repeal of Code chapter 124D (medical
  2 17 cannabidiol Act) before the repeal becomes effective July 1,
  2 18 2017.
       LSB 2301XS (2) 87
       rh/rj
  2 11 emergency rules which shall be effective immediately upon
  2 12 filing unless a later date is specified in the rules.  Any
  2 13 emergency rules adopted shall also be published as a notice of
  2 14 intended action as provided in Code section 17A.4, subsection
  2 15 1.
  2 16    The bill strikes the repeal of Code chapter 124D (medical
  2 17 cannabidiol Act) before the repeal becomes effective July 1,
  2 18 2017.
       LSB 2301XS (2) 87
       rh/rj
  2 12 filing unless a later date is specified in the rules.  Any
  2 13 emergency rules adopted shall also be published as a notice of
  2 14 intended action as provided in Code section 17A.4, subsection
  2 15 1.
  2 16    The bill strikes the repeal of Code chapter 124D (medical
  2 17 cannabidiol Act) before the repeal becomes effective July 1,
  2 18 2017.
       LSB 2301XS (2) 87
       rh/rj
  2 13 emergency rules adopted shall also be published as a notice of
  2 14 intended action as provided in Code section 17A.4, subsection
  2 15 1.
  2 16    The bill strikes the repeal of Code chapter 124D (medical
  2 17 cannabidiol Act) before the repeal becomes effective July 1,
  2 18 2017.
       LSB 2301XS (2) 87
       rh/rj
  2 14 intended action as provided in Code section 17A.4, subsection
  2 15 1.
  2 16    The bill strikes the repeal of Code chapter 124D (medical
  2 17 cannabidiol Act) before the repeal becomes effective July 1,
  2 18 2017.
       LSB 2301XS (2) 87
       rh/rj
  2 15 1.
  2 16    The bill strikes the repeal of Code chapter 124D (medical
  2 17 cannabidiol Act) before the repeal becomes effective July 1,
  2 18 2017.
       LSB 2301XS (2) 87
       rh/rj
  2 16    The bill strikes the repeal of Code chapter 124D (medical
  2 17 cannabidiol Act) before the repeal becomes effective July 1,
  2 18 2017.
       LSB 2301XS (2) 87
       rh/rj
  2 17 cannabidiol Act) before the repeal becomes effective July 1,
  2 18 2017.
       LSB 2301XS (2) 87
       rh/rj
  2 18 2017.
       LSB 2301XS (2) 87
       rh/rj
       LSB 2301XS (2) 87
       rh/rj
       rh/rj
